The global Nanoparticles - Metal & Metal Oxides Market in healthcare is anticipated to reach USD
80.74 billion by 2025, according to a new report by Grand View Research, Inc.
Several nanotechnologies-based medicines have been put forward for approval by
the FDA which is anticipated to propel growth.
Success of nanomedicine has
prompted the development of enhanced nanomaterials for clinical applications
with particular emphasis in therapy and diagnostics. This has resulted into the
significant production of metal oxide particles that hold potential utility in
human medicine.
Remarkable evolution has been
made in nanoparticle based medicines for theranostic applications in disease
management. Diverse metals have been used for development of medicines with a
promise to optimize the efficacy of nanomedicines and to improve the current
standard of medical and clinical practices.
These particles are recognized
to have major applications in drug delivery, diagnostic products, biomarker
discovery, and product packaging. Widespread application spectrum of these
particles in maintaining human health is expected to dramatically impact the
progress of this market in the coming years.
Moreover, metal oxides are
observed to have significant role in cancer treatment. Nanoparticle-augmented
systems enable high-concentration targeted drug delivery to cancer cells, which
in turn, is expected to enhance the usage rate of metal nanoparticles for
cancer treatment. Development of drug delivery strategies using nanoparticle
approaches are expected to bring about changes effective for cancer treatment.
However, prolonged exposure of
nanoparticles adversely affects the human health as well environment thereby
restraining their adoption rate. These products are involved in autophagy,
oxidative stress, lysosome dysfunction, and the activation of certain signaling
pathways, thereby exhibiting toxicity for human health.
Further key findings from the report suggest:
- Presence of untapped potential in alumina and
alumina oxide particles is anticipated to create immense opportunities
- Aluminum oxide in combination with polymeric
membranes is studied for enhancement of drug delivery owing to its high
porosity property displayed in the membranes
- This enhanced efficacy of the membrane
performance by the addition of alumina nanoparticles to polymeric
membranes is projected to increase its adoption
- Approval of various nanoparticle composition
and surface properties for clinical diagnostics and treatment of viral
infections is anticipated drive market demand
- In-vivo imaging dominated the
market with respect to revenue share
- Use of antibody conjugated to Au nanorods Raman
spectrum with polarized, sharpened, and enhanced results can be attributed
for larger revenue share
- Oncology dominated over a decade and is
projected to sustain its share over the forecast period.
- Rising incidence of cancer and other chronic
multi-drug resistant diseases pronounces the demand for these particles.
- Aforementioned factor is anticipated to drive
targeted delivery with fastest YoY growth
- Asia Pacific is projected to showcase lucrative
progress in the coming years
- Key countries in the region are working to
enhance the patient’s reach to nanotechnology-based solutions
- Moreover, continuous support from the
government bodies pertaining to initiation of new projects is expected to
play crucial role for projected CAGR
- Key players contributing in this market are
Pfizer Inc., Brigham Women's Hospital (BWH), Immunolight LLC, nanoComposix,
Nanobiotix, Nanospectra Biosciences, Inc, Merck KGaA, and AstraZeneca
- These participants are investing in development
of the product portfolio that can target the chronic disorders
- Arrowhead Pharmaceuticals, Cytimmune Sciences,
Inc, Nanobiotix, Celgene Corporation, Siteman Center of Cancer
Nanotechnology Excellence (Washington University CCNE), and BIND
Biosciences are few companies that have products in the pipeline phase
No comments:
Post a Comment